16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

NCT02159053 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Spondylitis, Ankylosing

Interventions

BIOLOGICAL: Secukinumab
BIOLOGICAL: Secukinumab
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals